According to a recent systematic review and meta-analysis the effect of ALC on VAS in patients with painful neuropathy was similar for different administration routes (intramuscular and oral sequential administration and oral administration only)
In a total of 140 pigmented mucosal lesions, they found 5 patterns including 67 structureless, 64 lines, 26 circles, 8 globules/clods, and 10 dots
for diabetes) and bremelanotide (Vyleesi
For neuroprotection protocols, standard dosing uses 0.25 to 0.5 mg daily via subcutaneous or oral administration
Vomiting, diarrhea, constipation, indigestion, abdominal discomfort, and decreased appetite have also been reported in retatrutide research